Nanomedicine in Cancer Immunotherapy

1st Edition - January 11, 2024
Editor: Prashant Kesharwani
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 7 7 0 - 4
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 8 7 7 1 - 1

Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often person… Read more

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Request a sales quote

Nanomedicine in Cancer Immunotherapy bridges the two disciplines of nanotechnology and immunology, summarizing the latest research into novel cancer treatments, often personalized to the patient. The book covers a wide range of nanomaterial types for use in cancer immunotherapy, including hydrogel, lipid, exosome, gold and peptide nanoparticles. The preparation, application, pros and cons of each nanomaterial class is reviewed, helping the reader understand the potential for each to tailor their own selections. Nanovaccines are also covered, along with a clinical evaluation and market analysis of nanomedicines for immunotherapy, offering an important clinical and commercial overview of this rapidly developing field.

This book is an interesting reference for those working in the fields of nanotechnology, immunology, and cancer therapeutics, as well as clinicians with an interest in novel nano-based cancer treatments.

Cover image
Title page
Table of Contents
Copyright
Dedication
List of contributors
About the editor
Preface
Acknowledgments
Chapter 1. Immunoadjuvants for cancer immunotherapy
Abstract
1.1 Why adjuvants for cancer immunotherapy?
1.2 Nanostructures for cancer immunotherapy
1.3 Viruses against cancer
1.4 Combined approaches for immunotherapy against cancer
1.5 Emerging cationic nanoadjuvants for cancer immunotherapy
Acknowledgments
References
Chapter 2. Nanotechnology as an emerging option in cancer immunotherapy
Abstract
2.1 Introduction
2.2 Traditional methods used in cancer treatment
2.3 Cancer immunotherapy
2.4 Different adoptive cellular transfer immunotherapies strategies for cancer
2.5 Nanotechnology-associated cancer immunotherapy strategies
2.6 Types of nanoparticles used in cancer immunotherapy
2.7 The targeted delivery of nanoparticles with cancer immunotherapy
2.8 Direct immune checkpoint inhibition with nanoparticles
2.9 Conclusion
References
Further reading
Chapter 3. Different administration routes for nanovectors in cancer immunotherapy
Abstract
3.1 Introduction
3.2 Types of nanovectors used in cancer immunotherapy
3.3 Deficiencies in delivery and efficacy of nanovectors
3.4 Nanovectors targeting mechanisms
3.5 Nanovectors’ administration routes
3.6 Transdermal delivery
3.7 Subcutaneous delivery
3.8 IV delivery
3.9 Oral delivery
3.10 Inhalation (pulmonary) delivery
3.11 Intramuscular delivery
3.12 Intraperitoneal delivery
3.13 Intranasal delivery
3.14 Rectal delivery
3.15 Vaginal delivery
3.16 IT delivery
3.17 Conclusion and future prospects
References
Chapter 4. Two-dimensional material–based nanomedicines for cancer immunotherapy
Abstract
4.1 Introduction
4.2 Main 2D materials and their applications in cancer immunotherapy
4.3 Summary and perspectives
Acknowledgments
Conflicts of interest
References
Chapter 5. Hydrogel-based nanomedicines for cancer immunotherapy
Abstract
5.1 Introduction
5.2 Nanotechnology and nanomedicine
5.3 Role of nanotechnology in cancer immunotherapy
5.4 Nanomaterials
5.5 Hydrogels
5.6 Hydrogel-based approaches in cancer immunotherapy
5.7 Conclusion and future perspective
References
Chapter 6. Exosomes-based nanomedicines for cancer immunotherapy
Abstract
6.1 Introduction
6.2 Exosomes for cancer immunotherapy
6.3 Summary
Acknowledgment
Conflict of interest
References
Chapter 7. Lipid-based nanomedicines for cancer immunotherapy
Abstract
7.1 Introduction
7.2 Cancer immunotherapy
7.3 Immunotherapeutic delivery systems
7.4 Different kinds of nanocarriers that are based on lipids
7.5 Oral lipid nanomedicines
7.6 Conclusions
References
Chapter 8. Inorganic nanoparticle-based nanomedicines for cancer immunotherapy
Abstract
8.1 Introduction of cancer immunotherapy
8.2 Advantages of inorganic nanomaterials
8.3 Silica nanomaterials for immunotherapy
8.4 Gold-nanomaterials for immunotherapy
8.5 Copper-nanomaterials for immunotherapy
8.6 Magnetic nanomaterials for immunotherapy
8.7 Carbon-nanomaterials for immunotherapy
8.8 Quantum dots for immunotherapy
8.9 Conclusion and perspective
Acknowledgments
Conflict of interests
References
Further reading
Chapter 9. Liposome-based nanomedicines for cancer immunotherapy
Abstract
9.1 Introduction
9.2 Cancer immunotherapy
9.3 Nanomedicine in cancer immunotherapy
9.4 Liposomes: an overview
9.5 Liposomes in cancer immunotherapy
9.6 Challenges and future prospects
9.7 Conclusion
Acknowledgement
Conflict of interest
References
Chapter 10. Biomembrane-based nanoparticles for cancer immunotherapy
Abstract
10.1 Red blood cell membrane-based nanoparticles
10.2 White blood cell membrane-based nanoparticles
10.3 Platelet membrane-based nanoparticles
10.4 Mesenchymal stem cell membrane-based nanoparticles
10.5 Cancer cell membrane-based nanoparticles
10.6 Bacterial membrane-based nanoparticles
10.7 Hybrid biomembrane-based nanoparticles
10.8 Conclusion and outlook
References
Chapter 11. Dendrimer-based nanomedicines for cancer immunotherapy
Abstract
11.1 Introduction
11.2 Synthesis and characterization of dendrimer nanoparticles
11.3 Dendrimers as general carriers for drug delivery
11.4 Dendrimer and enhancement of cancer immune responses
11.5 Dendrimers as vehicles for cancer immunotherapy
11.6 Dendrimer-based drug carriers in different cancers
11.7 Conclusions and future perspectives
References
Chapter 12. Magnetic nanocarriers for cancer immunotherapy
Abstract
12.1 Cancer immunotherapy
12.2 Magnetic nanocarriers
12.3 Magnetic nanocarrier for cancer immunotherapy
12.4 Definition of hyperthermia
12.5 Magnetic vaccination
12.6 Magnetic nanoparticle nanotheranostics
12.7 Conclusion
References
Chapter 13. Inhaled delivery of immunotherapy for treatment of lung cancer
Abstract
13.1 Types of lung tumors
13.2 Involvement of the immune system in the development of lung tumors
13.3 Potential immunotherapies for treatment of lung cancer
13.4 Limitations related to systemic immunotherapy
13.5 Advantages of pulmonary delivery of immunotherapy
13.6 Barriers facing pulmonary drug delivery
13.7 Efficient pulmonary drug delivery
13.8 Particulate systems criteria for efficient pulmonary drug delivery
13.9 Pulmonary drug delivery platforms
13.10 Examples of inhaled immunotherapy
References
Chapter 14. Nano-based vaccination and their administration routes in cancer immunotherapy
Abstract
14.1 Introduction
14.2 Antigens and vaccinations widely used in cancer treatment
14.3 Immunotherapy and cancer immunomodulation target cells
14.4 Potential of nanoparticle for cancer vaccination
14.5 Nanocarrier design and immunological response: the role of physicochemical properties
14.6 Systems for the delivery of cancer vaccines via nanoparticles
14.7 Clinical translation of cancer vaccines
14.8 Discussion
14.9 Conclusion
Data availability statement
Ethics statement
Acknowledgment
Funding
Conflict of interest
Author contributions
References
Chapter 15. Current status, challenges, and future perspective of nanomedicine-based cancer immunotherapy
Abstract
15.1 Introduction
15.2 Cancer immunotherapy
15.3 Types and features of nanoparticles used in cancer immunotherapy
15.4 Nanomedicines in cancer immunotherapy
15.5 The use of nanoparticles in cancer vaccines
15.6 Nanoparticles as immunotherapeutic agent carriers
15.7 The use of nanoparticles in monoclonal antibody therapy
15.8 Adoptive T-cell therapy using nanoparticles
15.9 Challenges of nanomedicine-based cancer immunotherapy
15.10 Future prospects
15.11 Conclusion
Acknowledgement
Conflict of interest
References
Index

Purchase options

LIMITED OFFER

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code is needed.

Institutional subscription on ScienceDirect

Prashant Kesharwani